Últimas noticias sobre Cue Biopharma (NASDAQ:CUE) Bolsa

Cue Biopharma

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Cue Biopharma Inc

Cuentas Inc

COPPEREX RES CORP by COPPEREX RES CORP

CUE ENERGY RESOURCES LTD by Cue Energy Resources Ltd.

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
SPY is currently trading around our key level of 576.62. Bulls need to maintain support at this level to push higher toward 577.87. If buyers can establish 577.87 as a solid floor, we anticipate a move to 579.12. Should momentum persist, the next upside target would be 580.67, with the potential to extend toward 600.51 if buying remains aggressive.
If SPY fails to hold 576.62, sellers may test the strength of 575.67. Continued weakness could drive the auction lower to 574.65. If that level gives way under sustained selling, the next key downside area is 573.50, with a potential drop to 572.15 if bears take full control of the session.
Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
QQQ is currently positioned around 495.35. If buyers can defend this level, we anticipate a push to 496.94. A breakout above that could lead to a test of 498.37. Strong bullish participation may extend the move to 499.44, with a high bull target for today set at 501.07.
Should 495.35 fail as support, we look for sellers to take charge, targeting 493.60. Increased bearish activity could bring a test of 491.82. If weakness persists, we expect 490.05 to be challenged, with further downside possibly extending to our low bear target of 487.69.
Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
Apple is currently auctioning near 234.20. Bulls need to establish support above this level to drive price action to 234.97. If strength continues, we anticipate a push to 235.74. Further upside momentum could bring 236.69 into play, with a high bull target of 237.49.
If 234.20 fails as support, we expect sellers to press for a move down to 233.28. If this level is lost, the next downside test is 231.76. Continued bearish pressure could bring a move to 230.25, with a potential extension lower to our bear target of 229.03.
Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)
Microsoft is currently positioned around 395.68. If bulls can sustain support at this level, a move toward 397.65 is in play. Holding above 397.65 would increase the likelihood of a push to 398.38. A strong session could see price action reaching our high bull target of 399.21.
If 395.68 fails as support, we look for the bears to drive the auction lower to 394.46. Further weakness could lead to a breakdown toward 393.47. If selling pressure remains dominant, we expect a move down to 392.49, with a low bear target of 390.98.
NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) NVIDIA is trading near 113.68, a key level to watch. If bulls can defend this area, we anticipate a push toward 114.29. A successful breakout could lead to a rally up to 115.15. Sustained bullish pressure may see a test of 115.83, with a high bull target of 116.61.
If 113.68 does not hold, bears are likely to drive the price lower to 112.54. A breakdown of that level could bring 111.70 into play. If weakness persists, we expect a test of 110.73, with further selling pressure potentially pushing price action to our low bear target of 109.86.
Alphabet Inc Class A (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)
Alphabet is currently trading around 171.14. Bulls need to maintain support at this level for an upward move to 172.28. Continued buying momentum could push price action toward 174.01, which serves as today's high bull target.
If 171.14 is lost as support, sellers will likely drive the auction lower to 169.34. A further breakdown could lead to a test of 167.04. If the bearish trend strengthens, the price may extend down to our low bear target of 165.41.
Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)
Meta is trading near 650.56. If bulls hold this level as support, we expect a move to 655.54. A continued uptrend could see price action testing 658.86, with a high bull target of 663.33 if buyers remain in control.
If 650.56 is lost as support, bears are likely to push for a test of 646.48. Additional selling could drive the price down to 642.59. If weakness persists, we look for a further move lower to our low bear target of 635.49.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla is auctioning around 272.42. Bulls need to hold this level for an attempt at 275.07. A strong move above 275.07 could bring 278.11 into play. If buyers sustain momentum, Tesla could reach 279.43, with a high bull target at 281.32.
If 272.42 does not hold as support, we expect sellers to test 269.48. A breakdown of this level could see price action move toward 266.83. If bearish pressure persists, we anticipate a further drop to our low bear target of 264.46.
Final Word:
Today&#8217;s economic calendar includes Initial and Continuing Jobless Claims at 8:30 AM ET, followed by Wholesale Trade Sales and Inventories for January at 10 AM ET. The Treasury will conduct 4-week and 8-week Bill Auctions at 11:30 AM ET. Additionally, we will hear from Fed members Harker, Waller, and Bostic, along with Treasury Secretary Bessent. As the market reacts to these catalysts, expect increased volatility. Manage risk effectively and trade with caution. Good luck!
The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day—hours before it&#8217;s published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Technicals

Signals

Pre-Market Outlook

ETFs

AAPL

GOOGL

MSFT

NVDA

TSLA

How To Trade SPY When Market Reacts To Key Catalysts

The European Central Bank on Thursday cut interest rates as expected and acknowledged that monetary policy is becoming "meaningfully<a href="https://www.benzinga.com/markets/forex/25/03/44161314/us-stocks-likely-to-open-lower-after-wednesdays-blip-be-patient-but-be-ready-to-act-says-analyst-as-market-uncertainties-can-create-opportunities"> less restrictive."</a>
The Details: The Governing Council lowered its three key interest rates by 25 basis points, bringing the deposit facility rate to 2.50%, the main refinancing rate to 2.65%, and the marginal lending rate to 2.90%.
"Monetary policy is becoming meaningfully less restrictive, as the interest rate cuts are making new borrowing less expensive for firms and households and loan growth is picking up," the ECB said in a statement.
Read Next: <a href="https://www.benzinga.com/news/econ-s/25/03/44143666/us-services-sector-unexpectedly-expands-in-february-despite-slowing-job-growth">US Services Sector Unexpectedly Expands In February Despite Slowing Job Gro</a>
Inflation projections show a gradual convergence towards the 2% target, with expectations of 2.1% in 2025, 1.9% in 2026, and 2% in 2027. Core inflation is also expected to approach the 2% target.
The Governing Council said it will maintain a data-dependent approach and be ready to adjust its instruments to ensure inflation stabilizes at the 2% medium-term target without committing to a specific rate path.&nbsp;
Markets React: European markets declined with the STOXX 50 and the STOXX 600 falling by 0.8%, after the European Central Bank delivered the interest rate cut.&nbsp;
Investors can monitor the Xtrackers MSCI Europe Hedged Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBEU#NYSE">DBEU</a>) and the SPDR Portfolio Europe ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPEU#NYSE">SPEU</a>)&nbsp; to gauge the U.S. market reaction to the cuts.&nbsp;
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), tracking the S&amp;P 500, was down 1.11% at $576.60 and the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), tracking the Nasdaq 100 index, was down 1.47% at $494.64 in Thursday's premarket session.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44110273/trump-tariffs-will-raise-prices-within-days-target-ceo-says">Trump Tariffs Will Raise Prices &#8216;Within Days,&#8217; Target CEO Says</a></li>
</ul>
Image: Shutterstock

News

Broad U.S. Equity ETFs

Eurozone

Emerging Market ETFs

Global

Econ #s

DBEU

SPEU

European Central Bank Cuts Interest Rates Marking Sixth Cut In 9 Months

WIIM

KITT

Nauticus Robotics shares are trading higher after the company announced the intent to acquire Seatrepid International.

Piper Sandler analyst Mark Lear maintains Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) with a Neutral and lowers the price target from $51 to $50.

Price Target

Analyst Ratings

Piper Sandler Maintains Neutral on Occidental Petroleum, Lowers Price Target to $50

Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced it has issued additional shares in conjunction with warrant exercises by investors and at-the-market stock sales. An additional 2,967,144 shares of common stock of the Company have been issued. The shares of common stock issuable upon exercise of the outstanding warrants were registered pursuant to a registration statements that was declared effective on May 8, 2024. The aggregate gross proceeds from the exercise of the existing warrants and at-the-market stock sales are expected to total approximately $2.3 million, before deducting financial advisory fees and commissions. After giving effect to the issuance of these additional shares, the Company has 20,421,617 shares of outstanding common stock.

Offerings

ONVO

Organovo Holdings Issues 2,967,144 Additional Shares Through Warrant Exercises and At-The-Market Stock Sales, Raising ~$2.3M In Gross Proceeds, Bringing Total Outstanding Shares to 20,421,617

Piper Sandler analyst Mark Lear maintains Murphy Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) with a Overweight and lowers the price target from $35 to $34.

Piper Sandler Maintains Overweight on Murphy Oil, Lowers Price Target to $34

-- The Simple, No-cost Test Can Detect Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Autoantibodies in the Blood with Only a Finger Prick --
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54219866&amp;newsitemid=20250306574544&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=7869700ed793696d9f0296d20b4454f8">Savara Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRA#NASDAQ">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the U.S., an evolution of the first serum-based assay the Company launched. The DBS test helps obtain a diagnosis of aPAP, a rare autoimmune lung disease caused by antibodies targeting GM-CSF, with only a finger-prick blood sample.
The DBS test demonstrates a high correlation between GM-CSF autoantibody levels in dried serum and traditional serum samples, ensuring reliable results, and has achieved 100% analytical sensitivity and specificity in a cohort of individuals with confirmed GM-CSF autoantibody status. The Company partnered with TrilliumBiO, a health solutions provider with a Clinical Laboratory Improvement Amendments (CLIA)-certified lab, to develop and validate the simple, no-cost, and noninvasive test.

Biotech

General

SVRA

Savara Announces U.S. Launch Of The aPAP ClearPath Dried Blood Spot Test To Detect Autoimmune Pulmonary Alveolar Proteinosis

Piper Sandler analyst Mark Lear maintains Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Neutral and raises the price target from $96 to $101.

Piper Sandler Maintains Neutral on Expand Energy, Raises Price Target to $101

&nbsp;
- ARO-INHBE and ARO-ALK7 both target a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies
- Data highlight Arrowhead's leadership in the use of RNA interference to potentially treat Obesity

Events

ARWR

Arrowhead Pharmaceuticals Presents Preclinical Data Supporting ARO-INHBE and ARO-ALK7 To Treat Obesity And Metabolic Diseases

Piper Sandler analyst Mark Lear maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Neutral and raises the price target from $35 to $36.

Piper Sandler Maintains Neutral on EQT, Raises Price Target to $36

Ohmyhome shares are trading lower after the company announced a 1-for-10 reverse stock split to be effective on March 10.

Explore what deepfake creators are doing to evade detection, the impact of generative AI on deepfakes, the escalating threats in cybersecurity, and mitigation tactics to combat AI-driven fraud
DENVER, March 06, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=rFOHMcqj_xFshal7LipmCBFFFJt5e8DlWGtVp-ynloq1_reYS16SU_A_1imtT7IO">authID</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>), a leading provider of biometric identity verification and authentication solutions, today released a comprehensive whitepaper detailing innovative approaches to combat the rising threat of deepfake fraud in digital authentication systems. The whitepaper, titled "Deepfake Countermeasures," provides crucial insights into deepfakes as the next generation in fraud attacks, as well as cutting-edge defensive strategies against presentation and injection attacks.
The increasing sophistication of AI platforms means attackers can use a single photo to synthesize deepfake videos. authID's report presents a critical framework for organizations to protect against a spike in identity fraud attempts and leverages authID's proprietary multi-layered detection system, which achieves a billion-to-one false-match accuracy rate. authID's platform detects the liveness of each authentication attempt, preventing the use of pictures, videos and deepfakes for spoofing identities, known as presentation attacks.

AUID

authID Publishes New Whitepaper On Next-Generation Deepfake Detection Technology Titled "Deepfake Countermeasures"

CYCU

Cycurion Partners With CentralSquare Technologies To Provide Public Safety IT Services

Piper Sandler analyst Mark Lear maintains EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) with a Neutral and lowers the price target from $141 to $135.

Piper Sandler Maintains Neutral on EOG Resources, Lowers Price Target to $135

ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>, or "ZyVersa"))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, today announced that it has entered into a securities purchase agreement with a single healthcare-focused U.S. institutional investor for the purchase and sale of 2,105,265 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,105,265 shares of common stock at an effective combined price of $0.95 per share and common warrant for aggregate gross proceeds of approximately $2.0 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $1.00 per share, will be exercisable immediately upon shareholder approval and will expire five years from the initial exercise date.
The closing of the offering is expected to occur on or about March 7, 2025, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering for general working capital.
A.G.P./Alliance Global Partners is acting as the sole placement agent in connection with the transaction.

ZVSA

ZyVersa Therapeutics Announces Pricing Of $2M Private Placement Priced At The Market

Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features&nbsp; of Systemic Sclerosis &nbsp;
TEL AVIV, Israel, March 06, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=7iF72dYqYIForA9mYcGm2LioRkwJo-D8darEBq2CyCSJdVooMoRIrOJIfUAPi3gadSYKb144QxsjXCtgJMQWuMo1xSfGTSctxDdvzOyvSgM=">Chemomab Therapeutics, Ltd</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced a new scientific presentation that further confirms the potential of nebokitug (CM-101) as a novel treatment for systemic sclerosis (SSc).1 The data will be presented at the <a href="https://www.globenewswire.com/Tracker?data=96J9V9lZEEXaaV4s9q1tzEexR1fMKSwwgereOBqnmCVF1xwKqCBsiRcUvSGYYD1NBd2mwDXtXUDcoHSH_MojM8L6_L5OYnR2XA0hBT0Y_9VKzH0WWY013rp0cutDL663VkqvKwTzSCweluKIY4Hmp9LDhTDoyO3UmPZLfVh_Bkg=">8th International Congress on Controversies in Rheumatology and Autoimmunity</a> (CORA 2025) on March 8, 2025, in Venice, Italy.
Systemic sclerosis is an autoimmune disease characterized by microvascular injury and extensive tissue fibrosis of the skin and internal organs. It is the most lethal of the systemic connective tissue diseases and lacks approved disease-modifying therapies. Nebokitug is a first-in-class monoclonal antibody that blocks the soluble protein CCL24, which has been shown to be a key driver of the pathways underlying fibro-inflammatory conditions such as SSc and primary sclerosing cholangitis (PSC). In extensive preclinical studies, blocking CCL24 reduced the inflammatory and fibrotic injury to the lung, skin and vasculature that are hallmarks of SSc pathology. An investigator-sponsored study showed that treatment with nebokitug induced strong and rapid reductions in inflammatory biomarkers in patients with acute lung Injury, a relevant model for the type of lung damage seen in SSc patients.

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

Chemomab Therapeutics Presents New Data Highlighting Clinical Potential Of Its Nebokitug In Systemic Sclerosis At CORA 2025 Conference

Lakeside Holding shares are trading higher after the company announced convertible debt financing of up to $4.5 million.

Piper Sandler analyst Mark Lear maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Overweight and raises the price target from $34 to $37.

CTRA

Piper Sandler Maintains Overweight on Coterra Energy, Raises Price Target to $37

Guidance

Macy's CEO Says Consumers Remain Under Pressure Navigating From An Inflation Rate And Yet Wanting To Indulge At Times; Says 'I Don't Think The Consumer Is Going To Feel A Sense Of Relief In The Short Term'

<ul>
<li>Proactive steps reinforce bioAffinity Technologies' laser focus on accelerating CyPath&#xAE; Lung sales growth in strategic national markets</li>
<li>Decreases labor and overhead costs, including 38% workforce reduction in non-CyPath&#xAE; Lung personnel at Company's subsidiary laboratory</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbioaffinitytech.com%2F&amp;esheet=54220116&amp;newsitemid=20250306388376&amp;lan=en-US&amp;anchor=bioAffinity+Technologies&amp;index=1&amp;md5=35df396edda935fc0a25014d8944a15f">bioAffinity Technologies</a>, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>, BIAFW)), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced targeted strategic actions to improve financial performance and accelerate the commercial growth of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cypathlung.com&amp;esheet=54220116&amp;newsitemid=20250306388376&amp;lan=en-US&amp;anchor=CyPath%26%23174%3B+Lung&amp;index=2&amp;md5=a255ade8a66b4dc2743693184fe3bafd">CyPath&#xAE; Lung</a>, the Company's noninvasive test for early-stage lung cancer. The Company expects these measures to deliver approximately $4 million in annual cost savings at its subsidiary Precision Pathology Laboratory Services (PPLS), while increasing resources to expand CyPath&#xAE; Lung sales in high-potential national markets.

BIAF

bioAffinity Technologies Announces Targeted Strategic Actions To Improve Financial Performance And Accelerate The Commercial Growth Of CyPath Lung; Expects These Measures To Deliver ~$4M In Annual Cost Savings

Management

Press Releases

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Financing

Cue Biopharma Announces Proposed Public Offering

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Health Care

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Cue Biopharma Announces Strategic Organizational Transition

Earnings

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Comments

Cue Biopharma

Noticias

Últimas noticias sobre Cue Biopharma (NASDAQ:CUE) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL